47 These authors jointly directed this work.
Tourette syndrome (TS) is highly heritable, although identification of its underlying genetic cause(s) has remained elusive. We examined a European ancestry sample composed of 2,435 TS cases and 4,100 controls for copy-number variants (CNVs) using SNP microarrays and identified two genome-wide significant loci that confer a substantial increase in risk for TS (NRXN1, OR=20.3, Approximately 1% of TS cases carried one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS.
Tourette syndrome (TS) is a complex developmental neuropsychiatric disorder of childhood onset characterized by multiple motor and vocal tics, with an estimated population prevalence of 0.3-0.9% 1 . Twin and family-based studies of TS have repeatedly demonstrated that it is highly heritable (e.g., h 2 of 0.77 in a recent analysis of the Swedish National Patient Register 2 ), while analysis of genome-wide SNP data suggests that TS risk is highly polygenic and distributed across both common and rare variation 3 . To date, the TS samples with available genome-wide genotyping have been inadequately sized for common variant association studies of a complex trait. To further characterize the genetic influences on TS, we assessed the impact of rare CNVs on disease risk, as it has been shown repeatedly that such variants contribute to susceptibility for other heritable neurodevelopmental disorders, including intellectual disability (ID), autism spectrum disorder (ASD) and schizophrenia (SCZ) 4 .
We genotyped TS cases and ancestry-matched controls on the same genome-wide SNP array platform (Illumina OmniExpress, Supplementary Table 1a ). Following standard quality control (QC) steps ( Supplementary Table 1b , Supplementary Figure 1 , and Supplementary Text), including genotype-based determination of ancestry ( Supplementary Figure 2 ), we analyzed CNVs in a SNP dataset of 6,535 unrelated European ancestry samples, including 2,435 individuals diagnosed with TS (by DSM-IV-TR criteria) and 4,100 healthy controls. To improve specificity, we generated CNV calls with two widely-used Hidden Markov Model (HMM)-based segmentation algorithms, PennCNV 5 and QuantiSNP 6 and retained the intersection of CNVs detected by both methods. We also conducted an additional QC step to test for any differential sensitivity in CNV detection between cases and controls, both within and across batches and sites, by analyzing CNV calls from 11 common HapMap3 CNVs using a sensitive locus-specific intensity clustering method, generating a total of 4,758 non-reference CNV calls across all samples ( Supplementary Figure 3) . Comparison of these genotypes with our consensus HMMbased calls confirmed the absence of any differential bias in the sensitivity of CNV detection between phenotypic groups whether assessed across all loci (p=0.53, Fisher's exact test) or between individuals (p=0.15, Welch's t-test, Supplementary Table 4 and Supplementary Text).
In total, we resolved 8,365 rare (as defined by a minor allele frequency [MAF] < 1% across all samples [50% reciprocal overlap]) CNV calls of at least 50 kbps in length and spanning a minimum of 10 probes. We assessed global CNV burden in terms of the number of CNVs, total CNV length, and the number of genes affected by CNVs, stratified by CNV type, size, and frequency. When considering all CNVs, we observed a modest but significant enrichment in TS across all metrics of burden for single-occurrence events ( Table 5 ).
In general, CNV burden for TS was greater with increasing event size and rarity, with the most substantial effect seen among large singleton deletions (>1 Mb), with an OR per CNV of 2.82 [1.36-6.18 ], p=7 × 10 -3 ( Figure 1 ). We next evaluated the dataset for possible enrichment of rare CNVs at specific loci, conducting a point-wise (segmental) test of association, treating deletions and duplications independently. As non-overlapping CNVs that affect the same gene would be unaccounted for by segmental assessments of enrichment, we also performed a complementary test collapsed on individual genes conditioned on exonic CNVs affecting protein-coding genes. In contrast to genome-wide association studies of SNPs, there is no generally accepted threshold to indicate genome-wide significance for CNVs. Therefore, for both tests, we established locus-specific (Plocus) and genome-wide corrected (Pcorr) p-values empirically through 1,000,000 permutations, using the max(T) method to control for familywise error rate (FWER) 7 . Both tests converged on the same two distinct loci, one for deletions and another for duplications, which were enriched among TS cases and survived correction for multiple testing.
For deletions, the peak segmental association signal was located at rs13418185 (Plocus=6 × 10 -6 , Pcorr=8.6 × 10 -4 , Figure 2a ), corresponding to heterozygous losses across the first three exons of NRXN1, found exclusively among TS cases (N=10, Figure 2a and b). In the gene-based test of genome-wide exonic CNVs, NRXN1 deletions were the most significant association (Supplementary Table 6 and Supplementary Figure 6 ), representing 12 cases (0.49%) and a single control (0.02%); OR=20.3 [2.6-156.2]; Plocus=6.2 × 10 -5 ; Pcorr=6.7 × 10 -4 . Consistent with deletions previously identified for this gene in ASD, SCZ, and epilepsy, these exon-spanning CNVs clustered at the 5' end of the gene and predominantly affected the α isoform of NRXN1 8 .
The most significant segmental association with a duplication was located within the CNTN6 gene at rs4085434 (Plocus=3.7 × 10 -5 , Pcorr=6.5 × 10 -3 ) with a secondary peak located directly upstream (Plocus=5.4 × 10 -5 , Pcorr=6.5 × 10 -3 , Figure 2a and c). Closer inspection of the locus revealed an enrichment of large duplications spanning this gene. A gene-based test determined that duplications overlapping CNTN6 correspond to an OR=10.1 [2.3-45.4] for TS (Plocus=2.5 × 10 -4 , Pcorr=8.3 × 10 -3 ), with gains found in 12 cases (0.49%) and 2 controls (0.05%) (Supplementary Table 6 and Supplementary Figure 7 ). All duplications detected across CNTN6 were heterozygous and spanned exons.
No other loci were significant after controlling for FWER, under either segmental or gene-based tests of association. We obtained similar results after pair-matching each individual case with its closest ancestrally matched control, demonstrating that these results are robust and not the result of inter-European population stratification or case-control sample biases (Supplementary Text and Supplementary Figure 8 ). Furthermore, we observed no significant enrichment of any CNVs among controls.
Excluding these two genome-wide significant loci, we conducted a secondary analysis testing for an increased burden among 27 rare, recurrent CNVs previously associated with various neurodevelopmental/neuropsychiatric disorders. We observed no nominally significant enrichment, either considering these CNVs individually ( Supplementary Table 7 ) or in concert (P=1.0, 2-sided Fisher's exact test).
Although previous studies have reported heterozygous exonic NRXN1 deletions in 4 TS patients 9,10 , the small sample sizes in these prior studies precluded any definitive association of this deletion with TS. Here, we demonstrate that exonic deletions affecting NRXN1, particularly those spanning exons 1-3, confer a substantial increase in risk for the disorder. Of note, among the 12 TS cases with exonic NRXN1 deletions, four had another previously diagnosed neurodevelopmental disorder (NDD), including two with ASD (Supplementary Table 8 ). The association of NRXN1 deletions with different neurodevelopmental disorders represents one of the most consistent findings regarding CNVs in neuropsychiatry 8, 11, 12 . Our data suggests an approximately two-fold higher prevalence of exonic NRXN1 deletions in TS compared to other neuropsychiatric disorders 12 , although much larger replication cohorts will be necessary to affirm this apparent comparative enrichment. Despite the diverse clinical presentation exhibited by NRXN1 deletion carriers, in vitro models using human neurons differentiated from induced pluripotent stem cells have shown independent lines carrying different exonic deletions in the NRXN1-ɑ isoform exhibit markedly similar defects in synaptic transmission 13 . NRXN1-ɑ interactions are also critical for thalamocortical synaptogenesis and plasticity 14 , underscoring a potential mechanism for its repeated association to developmental neuropsychiatric disorders.
Like NRXN1, CNTN6 encodes a cell-adhesion molecule that has been shown to promote neurite outgrowth. On the basis of structural variation, CNTN6 has been proposed as a candidate gene for intellectual disability and/or developmental delay 15, 16 , and deletions affecting CNTN6 are significantly enriched in ASD 17 . However, none of the subjects with CNTN6 duplications identified here had a known NDD ( Supplementary Table 8 ). Notably, the CNTN6 duplications identified in our sample are considerably larger in TS cases compared to controls (641.0 vs. 142.9 kbp). 9 out of 12 TS carriers harbor a duplication exceeding 500 kbp in length, while both of the CNTN6 duplications found in controls were less than 200 kbp. Furthermore, in a previous CNV study of 1,086 TS cases and 1,789 controls unrelated to the samples used in the current analysis, duplications directly upstream of CNTN6 demonstrated the greatest enrichment 18 , reinforcing a possible pathogenic significance of CNTN6 duplications to this disorder.
Consistent with northern blot analysis in the adult human nervous system 19 , examination of human brain RNAseq data from the BrainSpan project indicates that CNTN6 is widely expressed postnatally with highest expression seen both prenatally and postnatally in the cerebellum and mediodorsal thalamus, with additional focal expression in mid-gestational frontal and sensorimotor cortex (Supplementary Figure 9 ). The thalamus has long been a region of proposed involvement in TS based on multiple levels of evidence including thalamic lesions, human neurophysiology studies, and by recent treatments successes using deep-brain stimulation 20, 21 . The cerebellum has also recently been implicated in TS by functional magnetic resonance imaging 22 .
In summary, we have conducted the largest survey of structural variation in TS to date. We identified two genome-wide significant loci that are enriched for rare CNVs in TS: deletions in NRXN1 and duplications in CNTN6. Approximately 1% of TS cases carry a CNV in either gene.
Furthermore, we demonstrate a significant increase in global CNV burden, primarily for large, extremely rare deletions. This result suggests that additional CNVs that confer susceptibility to TS remain, but their discovery will likely require substantial increases in sample size.
Summarized Methods

Sample ascertainment and data generation
TS cases were ascertained through 21 sites across North America, Europe, and Israel through either specialty clinics or a web-based recruitment effort using a validated diagnostic instrument (TICS Inventory, Supplementary Text). A definite DSM-IV-TR diagnosis of TS, determined by an expert clinician, was a requisite for study inclusion. Unselected control samples were collected in conjunction with TS cases. Additional unscreened controls were obtained from four external studies, and SNP data was generated for all samples on the Illumina Figure 2a ). When samples exhibited an excessive amount of cryptic relatedness (PI-HAT > 0.185), only the sample with the higher call rate was retained. In addition, control samples that exhibited an excessive amount of cryptic relatedness to individuals clinically diagnosed with a neuropsychiatric phenotype were also removed.
Ancestry inference and matching
Genotype data was combined with data from publicly available HapMap samples of European, African, and Asian continental ancestry (Illumina). All available European (EU) population samples from the 1000 Genomes Project were also included to establish an appropriate calibration threshold for EU ancestry designation. A total of 19,024 LD-independent markers were used for ancestry inference, and samples were excluded if they contained > 0.0985 non-EU ancestry as determined using fastStructure (Supplementary Figure 2 ).
CNV calling
Only SNP assays common to all versions of the OmniExpress arrays were used for CNV detection (n=689,077) to mitigate any disparity in CNV detection due to probe coverage. Raw CNV calls were generated on all autosomal chromosomes using PennCNV and QuantiSNP. In addition to hard cutoffs used to flag problematic assays, samples were excluded if they represented outliers in a number of CNV quality metrics (determined as mean ±3 SD or by manual inspection, Supplementary Figure 1 ). Rare CNVs, defined by a prevalence of <1% across all samples, were validated with an alternative locus specific CNV genotyping algorithm that considers normalized, median-summarized intensity values across each putative CNV region.
An overview of the CNV processing pipeline is presented in Supplementary Figure 1 and described in detail in the Supplementary Text.
Burden analysis of global CNV burden
Under a logistic regression model, we assessed for global CNV burden as measured by the total number of CNVs, cumulative CNV length, or number of genes spanned by CNVs, including covariates found to be significantly associated with these burden metrics (Supplementary Text and Supplementary Table 9 ). Odds ratios indicate an increase in risk for TS per unit of CNV burden. P-values were calculated using the likelihood ratio test.
Locus-specific tests of association
The segmental test of association was performed at all unique CNV breakpoints. For gene-based association tests, we considered only CNVs spanning exons of coding genes as defined by Refseq annotation. Significance for both tests of association was determined by 1,000,000 permutations of phenotype labels. In each case, both locus-specific and genome-wide corrected p-values were obtained using the max(T) permutation method as implemented in PLINK v1.07, which controls for family-wise error rate by comparing the locus-specific test statistic to all test statistics genome-wide within each permutation.
Analysis of known neuropsychiatric susceptibility loci
A list of known CNVs with strong evidence of association to various neuropsychiatric disorders, including ASD, ID/DD, SCZ, and BD was assembled from the literature 4 
Supplementary Text
Sample Ascertainment
Tourette Syndrome (TS) cases were ascertained primarily from TS specialty clinics through sites distributed throughout North America, Europe and Israel as part of an ongoing collaborative effort by the Tourette Syndrome Association International Consortium for Genetics (TSAICG) as described in detail elsewhere 23 . Subjects were assessed for a lifetime diagnosis of TS, Obsessive Compulsive Disorder (OCD) and Attention-Deficit/Hyperactivity Disorder (ADHD) using a standardized and validated semi-structured direct interview (TICS Inventory 24, 25 ). An additional 628 cases were collected at 9 TS specialty clinics in Austria, Canada, France, Germany, Greece, Hungary, Italy and the Netherlands by expert clinicians using Tourette Syndrome Study Group criteria for Definite TS (DSM-IV TS diagnosis plus tics observed by a trained clinician) as well as DSM-IV diagnostic criteria for OCD and ADHD, along with 610 ancestry-matched controls as described previously 26 Lastly, in an effort to greatly increase sample size for TS genetic studies in a cost-effective manner, additional TS case samples were obtained through web-based recruitment of individuals with a prior clinical diagnosis of TS who subsequently completed an online questionnaire that we have validated against the gold-standard TS structured diagnostic interview with nearly 100% concordance for all inclusion/exclusion criteria as well as high correct classification rates for DSM-IV diagnoses of OCD and ADHD 25, 27 . Individuals for web- 
Genotyping and data processing
Cases and controls collected specifically for this study were all genotyped on the Illumina OmniExpress Exome v1.1, while the remaining control samples from the CC, CNP, GPC, and WTCCC2 cohorts were genotyped on the Illumina OmniExpress 12v1.0. The content of these two arrays is identical except for 1) exome-focused content on the former and 2) additional intensityonly markers on the latter. We have observed that exome-specific assays in general exhibit a much higher variance overall in their derived log-R ratio (LRR). Therefore, in order to avoid detection biases due to this differential variance, as well as from unequal probe coverage, only the SNP assays common to all versions of the OmniExpress arrays in this study were used for quality control (QC) and CNV detection, a total of 689,077 markers.
To ensure the generation of the most reliable SNP calls, intensity measures, and B-allele frequencies (BAF), as well as to reduce the effect of differential processing, a custom cluster file was generated for each individual genotyping batch. Since the performance of Illumina's proprietary normalization and cluster generation process is dependent on the number of samples, we processed all of the raw data, regardless of phenotype, with subsequent removal of clinical samples from the CNP and GPC datasets prior to analysis. An initial round of quality control (QC) was carried out using Illumina Beeline to determine baseline calling rates for each sample using the canonical cluster file (*.egt) provided by the manufacturer for each array version. Any sample with a call rate < 0.98 or a log-R ratio (LRR) standard deviation > 0.30 was deemed a failed assay and removed (Pre-cluster QC, Supplementary Table 1 ). SNP clustering was then performed in GenomeStudio with only passing samples within each genotyping batch.
This process was repeated for all datasets.
Genome-wide detection of CNV loci
We employed two widely-used HMM-based CNV calling algorithms, PennCNV (version 2011-05-03) and QuantiSNP (version 2.0), to initially detect structural variants in our dataset. We created GC-adjusted LRR intensity files for all samples using the GC-waviness correction method described by Diskin et al 30 . For PennCNV, a custom population B-allele frequency file was created for each genotyping batch separately and CNV calls were generated using the standard protocol. QuantiSNP calls were generated on the GC-adjusted intensity files. A concordant callset between both CNV callers was then generated by taking the intersecting boundaries of overlapping calls of the same CNV type (deletion or duplication). Additionally, adjacent CNV calls were merged if they were spanned by a CNV called by the other HMM algorithm. As HMMs have been shown to artificially break up large CNVs, we also merged CNV segments in the final concordant callset if they were of the same copy number and the number of intervening markers between them was less than 20% of the total of both segments combined.
We repeated this process iteratively until no more joining occurred.
Sensitivity assessment
Since the samples in this study were consolidated from multiple studies, subtle differences in the ability to detect genetic variation between cases and controls could lead to spurious associations. This issue is even more critical in studies involving CNVs, given the inherent imprecise nature of their detection.
Therefore, prior to association testing, we augmented a previously described method 7 to investigate whether any difference in sensitivity to detect CNVs existed between cases and controls within the context of our study. Both HMM-based CNV callers we employed for genome-wide detection are univariate methods completely agnostic of intensity information across multiple samples and do not use known population frequency prior probabilities in their calling algorithms. Therefore, common CNVs act as an ideal proxy to evaluate the effectiveness to detect rare events accurately, given that they are detected in the same manner but are present at much higher frequencies.
To facilitate data processing and visualization, we first generated an HDF5 database containing the LogR-Ratio (LRR) intensity and B-allele frequency (BAF) values for all samples. Normalized intensity values across each individual were generated by converting the GC-corrected, mediancentered LRR measures into Z-scores. We used the UCSC Genome Browser liftOver tool to translate a list of common HapMap3 CNVs to the hg19 reference. To match the thresholds used for our association tests in this study, we filtered the list of common CNVs to those that were >50 kbp in length. We reduced the number of markers required slightly to a minimum of 9 to ensure that an adequate number of events could be assessed. For each common CNV meeting these criteria, we examined the distribution of median-summarized normalized intensity measures within the CNV region across all study samples and retained only those loci that exhibited discrete clustering into distinct copy-number states. A total of 11 common CNV loci were retained for sensitivity analysis.
We generated locus-specific genotyping calls in the following manner. First, we extracted the LRR intensity Z-scores for all probes in the region across all samples. The Z-scores for all probes spanning the CNV locus were then subjected to a second round of normalization in order to normalize scores across all samples; this was found to aid in the automation of the clustering procedure. A Gaussian mixture model (GMM) was fit to this distribution to cluster samples into discrete CNV groups using the SciKit-learn Python package. The optimum number of clusters was automatically determined by minimization of the Bayesian Information Criterion (BIC) and corrected, when necessary, by manual inspection. Individuals were assigned to a cluster only if the posterior probability of assignment exceeded 0.95.
Copy number state was inferred by examining the original LRR intensity values for samples
within each cluster. We inspected for allele frequency differences between controls and cases for all clusters and found no significant difference (Fisher exact test, Supplementary Table 3 ). We collapsed the clusters at each locus into CNVs of the same type (deletion or duplication). As this locus-specific genotyping method is more sensitive than HMM segmentation methods, we used the proportion of concordant of HMM-based calls as a measure of segmentation detection sensitivity. We found no significant difference in sensitivity to detect common CNVs between phenotypic groups at any of the 11 loci tested, either independently, or in concert (Fisher exact test, Supplementary Tables 4a and 4b ). Furthermore, the mean sensitivity for each sample was calculated and collectively assessed for any systematic difference between phenotypic groups.
Considering duplications, deletions, or both in concert, we observed no significant difference in the sensitivity of segmentation calls between case and control groups (Welch t-test, Supplementary Table 4c ), thus validating our preprocessing, QC, and CNV-calling procedures.
Results obtained by fitting mixture models separately by either phenotype or batch produced similar results.
Call filtering, delineation of rare events, and in-silico validation
Calls were removed from the dataset if they spanned less than 10 markers, were less than 50kb in length, or overlapped by more than 0.5 of their total length with regions known to generate artifacts in SNP-based detection of CNVs, including immunoglobulin, telomeric (defined as 100kb from the chromosome ends) and centromeric regions, segmental duplications, and regions that have previously demonstrated associations specific to Epstein-Barr virus immortalized cell lines 29 . We filtered our callset for rare CNVs, defined as those events with MAF approximately < 1% (no more than 65 occurrences across 6,435 samples), based on a reciprocal overlap of 50% with CNVs of the same copy-number state. As the number of rare CNVs in a cohort such as ours is exceedingly large, traditional methods that rely on manual inspection of all putative CNV calls constitutes an approach that is both inconsistent and impractical. Therefore, for each putative rare CNV, we generated two different metrics based on intensity (LRR-Z) and BAF banding (BAFdel and BAFdup), and calculated population frequency estimates (OUTLIER-Z) by inspecting the distribution of intensities across the entire sample ( Supplementary Figure 4a) .
For qualifying CNVs based on intensity, we adopted a scoring methodology similar to the MeZOD method described previously 32, 33 , with a noted exception. We observed that standardized intensity measures from Illumina data typically range from < -20 for homozygous deletions, [-6,-2.5] for heterozygous deletions, and > 1.5 for duplications. Because of the disproportionately large effect on intensity measures caused by deletion events, performing a second round of normalization across all samples within each putative CNV often skews the overall distribution when such events are present. Therefore, we only performed a single round of normalization of LRR intensity measures within each sample. Each CNV is scored by calculating the median of LRR intensity Z-scores (LRR-Z) for all probes within the region. To determine reasonable thresholds for intensity metrics specific to our Omniexpress assay, we applied our CNV calling pipeline on 266 HapMap samples genotyped on the same OmniExpress platform, provided by Illumina. We compared these HapMap calls to those generated using high-coverage array comparative genome hybridization (aCGH) 34 . 11 samples overlapped between these two datasets. For these individuals, we extracted the LRR-Z for all aCGHvalidated CNV calls and inspected the distribution of all calls for both deletions and duplications in order to establish reasonable, conservative thresholds based on validated CNVs; in this case we required an LRR-Z of <-2.3 for deletions and >+1.3 for duplications ( Supplementary Figure   4b ).
The BAF banding pattern is particularly informative for the detection of CNV events using SNP arrays. This is particularly true for duplications, as intensity gains are typically modest for these types of events. We calculated the proportion of probes within the CNV region that showed and further inspected these regions manually. Putatively rare CNV loci that showed substantial evidence for extensive polymorphism were subsequently scored using the GMM genotyping method described above.
We opted not to impose any hard cutoff for CNV calls with regard to any of these measures to avoid any bias imposed by differential missingness derived from subtle systematic differences between genotyping batches. Rather, these thresholds were applied to flag those CNV calls with marginal scores for manual inspection and filter out only obviously misclassified events.
Through this in silico validation process, we discovered multiple instances of large copy-number aberrations likely due to individual mosaicism (Supplementary Figure 4c) , and two common polymorphic duplication regions misclassified as a rare CNV due to reduced sensitivity of the HMM segmentation ( Supplementary Figure 4d) . Out of 8,452 initial consensus HMM calls, a total of 87 CNV events were removed. Six of these were due to mosaic events, and the remainder was excluded due to the misclassification of common CNVs as a rare events.
Genome-wide burden analysis
For comparison of genome-wide burden between TS cases and controls, we limited our consideration to rare CNVs spanning a minimum of 10 SNPs and > 50kb in length. We assessed genome-wide CNV burden in three different ways: (1) number of rare CNVs, (2) total CNV length (per 100 KB), and (3) the total number of genes intersected by CNVs. Furthermore, we stratified each test by both size (all CNVs, >500kb, and >1Mb) as well as frequency (rare CNVs and singletons). Frequency counts were determined using PLINK --cnv-freq-method2 0.5.
Here, singletons are defined as sharing no more than a 50% overlap with any other CNV. Gene overlaps were counted if the CNV overlapped any gene boundary as delineated by Refseq. To examine the effect of different covariates on our different metrics of global CNV burden, we first fit a linear regression model for each type of burden test:
Burden_metric ~ genotyping_batch + subject_sex + LRR_SD + ancestry_PCs
None of the included covariates, which included the top 10 ancestry PCs, were significant predictors of global CNV burden as measured by either total number of CNVs or cumulative CNV length ( Supplementary Table 6a ). Separately, we examined the effect of these covariates exclusively with regard to the burden due to small CNV events, as these are most likely affected by minor fluctuations in assay quality and subtle differences in sample ascertainment. We found that LRR_SD was significantly associated with small CNV burden (defined here as CNVs < 100kb in length) for both total CNV number and CNV size ( Supplementary Table 6b and 6c), and was therefore included in the burden analysis as a covariate.
To assess for a global burden difference between TS and controls, we fit a logistic regression model in R with affectation status as the dependent variable and the burden metric and LRR_SD as independent variables. ORs indicate an increase in risk for TS as assessed per CNV, per 100kb of total CNV length, or per gene affected by CNVs. P-values were calculated using the likelihood ratio test.
Validation of association results
We repeated the segmental association test after carefully pair-matching each case with a control such that the global difference between each pair was minimized using SpectralGEM 32 ( Supplementary Figure 8) . For the matched segmental association analysis, because of the drastic reduction in sample size, a corrected p-value < 0.05 was used as a cutoff to indicate genome-wide significance.
Figure 1. Global CNV burden in Tourette Syndrome (TS) increases with both size and rarity of events.
Forest plots show OR and 95% CI estimates for an increased risk for TS per CNV, determined by fitting a logistic regression model of phenotype status against CNV count with significant covariates (Supplementary methods). All CNVs considered are >50kb in length and span a minimum of 10 probes. Rare CNVs denote events with a MAF < 0.01; singletons occur only once in either a case or control, corresponding to a MAF of approximately 0.00015 in this study. P-values are calculated using the likelihood ratio test. Box sizes are proportional to precision.
Figure 2. Significant loci enriched for CNVs in TS.
(a) Manhattan plot of the results from segmental association tests reveal two genome-wide significant loci: deletions at NRXN1 and duplications at CNTN6. Association tests were conducted separately for gains and losses; for clarity, p-values displayed are empirically corrected for FWER genome-wide using the max(T) method with 1,000,000 permutations and plotted together here. Significance levels representing an ɑ of 0.05 and 0.01 are depicted by blue and red lines, respectively. (b) Heterozygous deletions show a peak of segmental association near the 5' end of NRXN1 (p=6.0 × 10 -6 ). Deletions spanning the first three exons are found in 10 cases and no controls (blueshaded bar). Deletions affecting any exon (Supplementary Figure 6) were found in 12 cases (0.49%) and 1 control (0.03%), corresponding to an OR=20.3, 95% CI (2.6-156.2). (c) Structural variation at the CNTN6 locus. For duplications, the peak of segmental association was located within the CNTN6 gene (p=3.7 × 10 -5 ). Duplications overlapping this gene correspond to an OR=10.1, 95% CI (2.3-45.4), with heterozygous gains found in 12 cases (0.49%) and 2 controls (0.05%). CNVs overlapping CNTN6 are considerably larger in cases compared to controls (640.0 vs. 142.9 kb, on average). Figure 8 . Examination for population-specific effects. To verify the robustness of our results to population stratification, we pair-matched each case subject with exactly one case such that the global difference between all pairs is minimized using SpectralGEM. We also excluded all outlying pairs based on the genetic distance between them (>90th percentile Supplementary Table 7 . Prevalence of known, recurrent, neuropsychiatric CNVs in TS. Known CNVs were considered present in a sample if it carried a variant of the same CNV type (deletion/duplication) and overlapped at least 50% the length of the known recurrent CNV, except for the single-gene locus containing VIPR2, where the associated signal has been shown to derive from non-recurrent events 37 . For this locus, any CNV > 50kb overlapping any portion of the gene was counted. P-values were determined with 100,000 permutations using the max(T) method to control for the family-wise error rate. P-values corrected empirically for multiple testing are shown in parentheses, with two-sided p-values presented only when there is enrichment in controls. Supplementary Figure 9 . Spatio-temporal expression of CNTN6 in human brain. Analysis of RNASeq data from Brainspan (www.brainspan.org) indicates that CNTN6 is most highly expressed postnatally in the cerebellum (CBC) followed by the thalamus (MD). Heatmap represents median expression values for all available samples at each tissue normalized across each developmental timepoint. Regions: primary visual cortex (V1C), inferolateral temporal cortex (ITC), posteroventral parietal cortex (IPC), primary auditory cortex (A1C), posterior superior temporal cortex (STC), primary motor cortex (M1C), primary somatosensory cortex (S1C), ventrolateral prefrontal cortex (VFC), anterior cingulate cortex (MFC), dorsolateral prefrontal cortex (DFC), orbital frontal cortex (OFC), striatum (STR), hippocampus (HIP), amygdaloid complex (AMY), mediodorsal nucleus of thalamus (MD), cerebellar cortex (CBC). Temporal abbreviations: post-conception weeks (pcw), months (mos), years (yrs). Supplementary Table 9 . Regression models of global CNV burden. (a) Results from a linear regression model of global burden with total CNV count as the dependent variable, and genotyping batch, subject sex, LogR-Ratio standard deviation (LRRSD, a general metric for CNV assay quality), and the top 10 ancestry PCs as dependent variables. None of the included covariates were significant predictors of global CNV burden in terms of CNV count or total CNV size (Supplementary Text). However, when restricted to small CNV events (<100kb), LRRSD was a significant predictor of CNV burden in terms of (b) total CNV count and (c) total CNV length; therefore LRRSD was included as a covariate in our subsequent analysis.
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